Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade C 52.67 2.87% 1.47
RARE closed up 4.98 percent on Tuesday, January 15, 2019, on approximately normal volume. It was able to find support at its 50 day moving average. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical RARE trend table...

Date Alert Name Type % Chg
Jan 15 50 DMA Support Bullish 2.87%
Jan 15 MACD Bullish Centerline Cross Bullish 2.87%
Jan 15 Upper Bollinger Band Walk Strength 2.87%
Jan 15 Multiple of Ten Bullish Other 2.87%
Jan 15 Wide Bands Range Expansion 2.87%
Jan 15 Above Upper BB Strength 2.87%
Jan 15 Overbought Stochastic Strength 2.87%
Jan 15 Upper Bollinger Band Touch Strength 2.87%
Jan 14 50 DMA Support Bullish 8.00%
Jan 14 Upper Bollinger Band Walk Strength 8.00%

Older signals for RARE ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
Is RARE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 90.98
52 Week Low 37.44
Average Volume 565,568
200-Day Moving Average 65.8035
50-Day Moving Average 48.4682
20-Day Moving Average 44.0415
10-Day Moving Average 45.971
Average True Range 2.9116
ADX 27.79
+DI 23.2094
-DI 16.1439
Chandelier Exit (Long, 3 ATRs ) 42.8952
Chandelier Exit (Short, 3 ATRs ) 46.1748
Upper Bollinger Band 50.803
Lower Bollinger Band 37.28
Percent B (%b) 1.03
BandWidth 30.70513
MACD Line 0.1198
MACD Signal Line -1.2702
MACD Histogram 1.39
Fundamentals Value
Market Cap 2.18 Billion
Num Shares 42.6 Million
EPS -6.74
Price-to-Earnings (P/E) Ratio -7.60
Price-to-Sales 16800.34
Price-to-Book 4.53
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 56.06
Resistance 3 (R3) 55.66 53.65 55.25
Resistance 2 (R2) 53.65 52.41 53.85 54.98
Resistance 1 (R1) 52.42 51.64 53.04 52.82 54.71
Pivot Point 50.41 50.41 50.71 50.61 50.41
Support 1 (S1) 49.18 49.17 49.80 49.58 47.69
Support 2 (S2) 47.17 48.40 47.37 47.42
Support 3 (S3) 45.94 47.17 47.15
Support 4 (S4) 46.34